Valneva Shares Navigate Dual Challenges Amid Vaccine Developments

Valneva stock pressured as Lyme disease vaccine faces statistical review, but partner Pfizer plans 2026 filings. Chikungunya vaccine gains real-world traction in Brazil with 500k dose supply ready.

Valneva finds itself in the spotlight this week, with significant news emerging on two of its key vaccine programs simultaneously. The biotech company's stock is caught between promising real-world data for its chikungunya vaccine and statistical complexities surrounding its Lyme disease candidate.

Lyme Disease Candidate Faces Statistical Hurdle, But Partner Stays Committed

Analysts at First Berlin Equity Research have revised their price target for Valneva shares downward from €6.60 to €4.80, though they maintain a 'buy' recommendation. This adjustment follows a deeper statistical review of Phase 3 trial data for LB6V, the Lyme disease vaccine being developed in collaboration with Pfizer.

The trial demonstrated an efficacy rate exceeding 70% in participants aged five and older, with no significant safety concerns identified. However, the data did not meet the pre-specified statistical threshold in the first pre-defined analysis. Consequently, First Berlin has reduced its internal assessment of the vaccine's approval probability from 90% to 67%.

Pfizer, Valneva's partner on the project, holds a more optimistic view. The pharmaceutical giant points out that the second pre-defined analysis did achieve its statistical endpoint. Furthermore, the trial recorded fewer actual Lyme disease cases than initially anticipated. Based on this, Pfizer plans to submit LB6V for regulatory approval with both the U.S. FDA and the European EMA in 2026. This candidate remains the most advanced human vaccine in development globally for Lyme disease, a market currently without any approved preventative treatment.

Chikungunya Vaccine Gains Ground with Evidence from Brazil

In a separate but concurrent development, Valneva presented Phase IV data and real-world evidence for its single-dose chikungunya vaccine, IXCHIQ, at the World Vaccine Congress in Washington. The findings are drawn from an ongoing pilot program in Brazil, a country chosen for its high disease burden.

Brazil reported over 263,000 chikungunya cases and 246 related deaths in 2024 alone. In April 2025, it became the first endemic country worldwide to grant market authorization for IXCHIQ. Under this program, more than 12,000 individuals across ten communities have already been vaccinated, with a target coverage of 20 to 40 percent of the at-risk population. Valneva, through its partner Instituto Butantan, is prepared to supply up to 500,000 doses to Brazil's Ministry of Health.

Market Reaction and Future Outlook

The contrasting news flow is reflected in Valneva's share price, which currently trades at €2.83. This represents a decline of approximately 45% from its 52-week high of €5.16, reached in August 2025, and a drop of over 40% in the past 30 days.

First Berlin's financial projections estimate a per-share loss of €0.37 for Valneva in 2026, turning to a profit of €0.78 per share in 2027. The firm notes that the accuracy of this forecast hinges critically on the successful submission of LB6V to regulators this year and how authorities interpret the mixed trial results. The company's near-term valuation appears tightly linked to resolving the statistical uncertainty surrounding its Lyme disease program, even as its chikungunya vaccine builds a compelling case in the field.